ONVO - Organovo Holdings, Inc.
| Previous Close | 1.08 |
| Open | 1.07 |
| Bid | 1.05 x 1000 |
| Ask | 1.10 x 3200 |
| Day's Range | 1.06 - 1.12 |
| 52 Week Range | 0.91 - 2.09 |
| Volume | 525,371 |
| Avg. Volume | 579,832 |
| Market Cap | 123.659M |
| Beta (3Y Monthly) | 2.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 |
| Earnings Date | Nov 8, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.58 |
- GlobeNewswire•2 days ago
Organovo Announces Release Date for Fiscal Second-Quarter 2019 Financial Results
Organovo Holdings, Inc. (ONVO) (“Organovo”) will host a conference call on Thursday, November 8, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal second-quarter 2019 operating and financial highlights. In advance of the call on November 8, 2018, Organovo will issue its fiscal second-quarter 2019 earnings press release, which will be available at http://www.organovo.com.
- GlobeNewswire•3 days ago
Report: Exploring Fundamental Drivers Behind Shenandoah Telecommunications, Nova Measuring Instruments, FRP, National Fuel Gas, Organovo, and Sierra Wireless — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•5 days ago
Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)
SAN DIEGO, Oct. 15, 2018 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a.
- GlobeNewswire•24 days ago
Organovo to Present at 2018 Cell & Gene Meeting on the Mesa
Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Executive Officer, Taylor J. Crouch, is scheduled to speak at the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, Ca. This conference is the largest partnering meeting organized specifically for the cell and gene therapy sector, providing the opportunity for participants to establish key relationships and accelerate business development. Organized by ARM and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts, the program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.
- Simply Wall St.•last month
Is Organovo Holdings Inc’s (NASDAQ:ONVO) Balance Sheet A Threat To Its Future?
The direct benefit for Organovo Holdings Inc (NASDAQ:ONVO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ONVO earnings conference call or presentation 9-Aug-18 9:00pm GMT
Q1 2019 Organovo Holdings Inc Earnings Call
- GlobeNewswire•2 months ago
Recent Analysis Shows Ellie Mae, Organovo, Calithera Biosciences, Whirlpool, Marathon Oil, and Infinera Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie ...
- GlobeNewswire•2 months ago
Organovo Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Organovo Holdings, Inc. (ONVO) (“Organovo” or the “Company”) announced the grant of inducement awards on August 14, 2018 to Dr. Steven G. Hughes, its new chief medical officer. The inducement awards were approved by the compensation committee of the Company’s board of directors and issued as a material inducement to Dr. Hughes agreeing to join the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
- Benzinga•2 months ago
The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 9) Acer Therapeutics Inc (NASDAQ: ACER )(HC Wainwright reiterated ...
- Zacks•2 months ago
Organovo (ONVO) Reports Q1 Loss, Misses Revenue Estimates
Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -40.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Organovo: Fiscal 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 7 cents. The development-stage company focused on commercializing functional human tissue for drug and biological research posted ...
- GlobeNewswire•2 months ago
Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals
Pre-Investigational New Drug meeting with the FDA expected to be held in calendar 2019 Lead IND program for Alpha-1-antitrypsin deficiency expected to commence IND-enabling studies in second half of calendar ...
- ACCESSWIRE•2 months ago
Organovo Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Organovo Holdings, Inc. (NASDAQ: ONVO ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 9, 2018 at 5:00 PM Eastern ...
- GlobeNewswire•3 months ago
Organovo Announces Appointment of Steven G. Hughes, M.D. as Chief Medical Officer
Organovo Holdings, Inc. (ONVO) (“Organovo”) today announced that Steven G. Hughes has been named Chief Medical Officer. Dr. Hughes is an industry veteran who brings significant experience directing clinical development and medical affairs teams at leading biopharma companies. Dr. Hughes most recently served as the Chief Clinical Development Officer at Ionis Pharmaceuticals, where he led a team that managed the global clinical development of 25 drugs across 10 therapeutic areas including cardiovascular, metabolic, oncology and rare diseases. Previously, he held positions as Global Medical Lead, Oncology Clinical Development and Medical Director, UK & Ireland at Biogen Idec. Dr. Hughes also held numerous senior clinical development, medical affairs and leadership positions of increasing responsibility at CSL Behring and Sanofi. Dr. Hughes is board certified in Pharmaceutical Medicine and received his medical degree from Imperial College, London. He also has an MBA with distinction from Imperial College Business School.
- ACCESSWIRE•3 months ago
Free Pre-Market Technical Recap on ResMed and Three Additional Healthcare Stocks
On Thursday, July 19, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: OraSure Technologies Inc. (NASDAQ: OSUR), ResMed Inc. (NYSE: RMD), OpGen Inc. (NASDAQ: OPGN), and Organovo Holdings Inc. (NASDAQ: ONVO). On Thursday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 373,287 shares.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of ONVO earnings conference call or presentation 31-May-18 9:00pm GMT
Q4 2018 Organovo Holdings Inc Earnings Call
- Motley Fool•5 months ago
Here's Why Organovo Holdings Stock Fell as Much as 28.4% Today
The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.
- Associated Press•5 months ago
Organovo: Fiscal 4Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 7 cents. The development-stage company focused on commercializing functional human tissue for drug and biological research posted ...
- Benzinga•5 months ago
Organovo Q4 Earnings Preview
On Thursday, Organovo Holdings (NYSE: ONVO ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Organovo EPS ...
- ACCESSWIRE•5 months ago
Free Stock Performance Review on Organovo Holdings and Three Additional Medical Research Stocks
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.
- Simply Wall St.•5 months ago
Want To Invest In Organovo Holdings Inc (NASDAQ:ONVO)? Here’s How It Performed Lately
After reading Organovo Holdings Inc’s (NASDAQ:ONVO) most recent earnings announcement (31 December 2017), I found it useful to look back at how the company has performed in the past andRead More...
